- 2 -

PC 25562

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

Claim 1 (previously amended): A c

A compound of Formula II or III I

$$R^{2}$$
 $R^{3}$ 
 $R^{4}$ 
 $R^{6}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{7}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{7}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{1}$ 

or a pharmaceutically acceptable salt thereof, wherein

 $R^1$  and  $R^2$  are independently hydrogen or unsubstituted  $C_1\text{-}C_3$  alkyl;

\_

PC 25562

R<sup>3</sup> is hydrogen, oxo, or thioxo;

R<sup>0</sup>-is hydrogen or unsubstituted C<sub>1</sub>-C<sub>2</sub> alkyl provided that when R<sup>3</sup>-is exe or thiexe R<sup>0</sup> is absent;

- R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently hydrogen, halogen, carboxyl, substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkoxy, or substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl;
- Q is -NR<sup>8</sup>-(CH<sub>2</sub>)<sub>0-6</sub>-, -NR<sup>9</sup>-C(O)-(CH<sub>2</sub>)<sub>0-6</sub>-, wherein 1 to 3 nonadjacent methylene units are replaced with O, NR<sup>10</sup>, S or a combination thereof;

T is substituted or unsubstituted aryl;

W is absent, substituted or unsubstituted aryl;

- Z is -(CH<sub>2</sub>)<sub>0-6</sub>-cycloalkylene-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof.
  - -(CH<sub>2</sub>)<sub>0-6</sub>-heterocycloalkylene-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof,
  - -(CH<sub>2</sub>)<sub>0-6</sub>-arylene-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof,
  - -(CH<sub>2</sub>)<sub>0-6</sub>-heteroarylene-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof,
  - -(CH<sub>2</sub>)<sub>0-6</sub>-C(O)-NR<sup>11</sup>-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof,
  - -(CH<sub>2</sub>)<sub>0-6</sub>- NR<sup>11</sup>-C(O)-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof,

$$- \left( \begin{matrix} R^{15} \\ C \\ R^{14} \end{matrix} \right)_{1-12}$$

wherein 1 to 6 nonadjacent R<sup>14</sup> units are replaced with O, NR<sup>12</sup>, S or a combination thereof, or

Z, when W is absent, is hydroxyl, substituted or unsubstituted  $C_1$ - $C_{12}$  alkyl wherein 1 to 6 nonadjacent methylene units are replaced with O, NR<sup>16</sup>, S or a

- 4 -

PC 25562

combination thereof, or  $-(CH_2)_{0-6}$ -C(O)- $NR^{16}$ - $(CH_2)_{0-5}$ - $CH_3$  wherein 0 to 6 nonadjacent methylene units are replaced with O,  $NR^{16}$ , S or a combination thereof;

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently hydrogen or substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl; R<sup>11</sup> and R<sup>12</sup> are independently substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl; and

R<sup>14</sup> and R<sup>15</sup> are independently hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkoxy, substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>12</sub> alkyl wherein 1 to 6 nonadjacent methylene units are replaced with O, or R<sup>14</sup> and R<sup>15</sup> together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene or heterocycloalkylene ring; and

R<sup>16</sup> is substituted or unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl or hydrogen.

Claim 2 (original): A compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup>, are hydrogen and R<sup>3</sup> is oxo.

Claim 3 (original): A compound of claim 1, wherein  $R^4$ ,  $R^5$ ,  $R^6$ , and  $R^7$  are independently hydrogen, halogen, carboxyl,  $C_1$ - $C_3$  alkoxy, or  $C_1$ - $C_3$  alkyl.

Claim 4 (original): A compound of claim 3, wherein  $R^4$ ,  $R^5$ ,  $R^6$ , and  $R^7$  are independently hydrogen, chlorine, fluorine, carboxyl, methoxy or methyl.

Claim 5 (original): A compound of claim 1, wherein R<sup>4</sup>, R<sup>6</sup>, and R<sup>7</sup> are hydrogen and R<sup>5</sup> is chlorine, fluorine, carboxyl, methoxy or methyl.

Claim 6 (original): A compound of claim 1, wherein Q is  $-NR^8$ -(CH<sub>2</sub>)<sub>0-6</sub>-, or  $-NR^9$ -C(O)-(CH<sub>2</sub>)<sub>0-6</sub>- wherein  $R^8$  and  $R^9$  are independently unsubstituted C<sub>1</sub>-C<sub>3</sub> alkyl.

Claim 7. (original): A compound of claim 6, wherein Q is -NH-(CH<sub>2</sub>)<sub>0-6</sub>-, or -NH-C(O)-(CH<sub>2</sub>)<sub>0-6</sub>-.

- 5 -

PC 25562

Claim 8 (original): A compound of claim 7, wherein Q is -NH-CH<sub>2</sub>-, -NH -CH<sub>2</sub>-CH<sub>2</sub>-, -NH-CH<sub>2</sub>-CH<sub>2</sub>-O-CH<sub>2</sub>-, or -NH-CH<sub>2</sub>-CH<sub>2</sub>-O-.

Claim 9 (original): A compound of claim 1, wherein T is unsubstituted aryl.

Claim 10 (currently amended): A compound of claim 1, wherein T is unsubstituted phenyl, naphthyl, biphenyl, or 1,2,3,4-tetrahydro-naphthyl, 1,2,3,4-tetrahydroquinoxalinyl, or 1,2,3,4-tetrahydroindolyl.

Claim 11 (previously amended): A compound of claim 10, wherein T is 2-naphthyl or biphen-4-yl.

Claim 12 (original): A compound of claim 1, wherein T is substituted aryl

Claim 13 (currently amended): A compound of claim 12, wherein T is substituted phenyl, naphthyl, biphenyl, or 1,2,3,4 tetrahydroquinolinyl, 2-oxo-1,2,3,4 tetrahydroquinolinyl, 1,2,3,4-tetrahydro-naphthyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,2,3,4-tetrahydroindolyl, 2,3-dihydroindolyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl, or 3,4-dihydro-2H-benzo[1,4]oxazinyl.

Claim 14. (original): A compound of claim 12, wherein T is phenyl substituted from 1 to 5 times with  $C_1$ - $C_6$  alkyl, halo,  $C_1$ - $C_6$  alkyl wherein 1 to 3 nonadjacent carbons are replaced with O,  $NR^{16}$ , S or a combination thereof,  $(C_1$ - $C_6$  alkyl)-C(O)-O- $(C_1$ - $C_6$  alkyl)O-O- $(C_1$ -O- $(C_1$ - $(C_1$ -

Claim 15. (original): A compound of claim 14, wherein T is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-

- 6 -

PC 25562

chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-fluoro-2-trifluoromethylphenyl, 2-(2-acetoxy-ethyl)-phenyl, 3-(2-acetoxy-ethyl)-phenyl, 4-(2-acetoxy-ethyl)-phenyl, N,N-dimethyl-benzamide-4-yl, or 4-acetylaminophenyl.

Claim 16 (original): A compound of claim 1, wherein T is biphenyl substituted from 1 to 9 times with C<sub>1</sub>-C<sub>6</sub> alkyl, halo, C<sub>1</sub>-C<sub>6</sub> alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR<sup>16</sup>, S or a combination thereof, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-O-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-N(R<sup>16</sup>)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-NR<sup>16</sup>-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, HO-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(O)<sub>2</sub>-NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-NR<sup>16</sup>-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, or HO-(C<sub>1</sub>-C<sub>6</sub> alkyl), wherein each R<sup>16</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl or a combination thereof.

Claim 17 (currently amended): A compound of claim 1, wherein T is <u>unsubstituted</u> naphthyl, or 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl naphthyl substituted from 1 to 7 times with, C<sub>1</sub>-C<sub>6</sub> alkyl, halo, hydroxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR<sup>16</sup>, S or a combination thereof, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-O-(C<sub>1</sub>-C<sub>6</sub> alkyl)-O-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-N(R<sup>16</sup>)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-NR<sup>16</sup>-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, or HO-(C<sub>1</sub>-C<sub>6</sub> alkyl), wherein each R<sup>16</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl or a combination thereof.

Claim 18 (previously amended): A compound of claim 17, wherein T is 6-methoxy-2-naphthyl, 7-methoxy-2-naphthyl, 6-methyl-2-naphthyl, 6-hydroxy-2-naphthyl, 7-methyl-2-naphthyl, 6-trifluoromethyl-2-naphthyl, 7-trifluoromethyl-2-naphthyl, 6-fluoro-2-naphthyl, 7-fluoro-2-naphthyl, 6-chloro-2-naphthyl, 7-chloro-2-naphthyl, 6-(2-acetoxy-ethyl)-2-naphthyl or 7-(2-acetoxy-ethyl)-2-naphthyl.

- 7 -

PC 25562

Claim 19 (currently amended): A compound of claim 1, wherein T is unsubstituted naphthyl, unsubstituted 4 trifluoromethylphenyl, 4 (2 ethoxy 2 oxoethyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin 6 yl, 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin-6 yl, 4 (3 methoxypropyl) 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin-6 yl, 4 (2 acetylaminoethyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin-6 yl, 4 (2 acetoxyethyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin-6 yl, 4 (2 acetoxyethyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin-6 yl, 4 (3 methoxy-3 oxopropyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin-6 yl, 4 (2 methoxy-2 oxoethyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin-6 yl, 1 (2 methoxy-2 oxoethyl) 3 oxo-3,4 dihydro-2H benzo[1,4]oxazin-6 yl,

Claims 20-28 (canceled)

Claim 29 (original): A compound of claim 1, wherein Z is

$$\begin{array}{c|c}
 & R^{15} \\
 & C \\
 & R^{14}
\end{array}$$

wherein 1 to 6 nonadjacent

units are replaced with O.

Claim 30 (original): A compound of claim 1, wherein R<sup>14</sup> and R<sup>15</sup> are hydrogen.

Claim 31 (original): A compound of claim 1, wherein Z is
-(CH<sub>2</sub>)<sub>0-6</sub>-C(O)-NR<sup>11</sup>-(CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O,
NR<sup>12</sup>, S or a combination thereof; or

-(CH<sub>2</sub>)<sub>0-6</sub>- NR<sup>11</sup>-(C(O)-CH<sub>2</sub>)<sub>0-6</sub>- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR<sup>12</sup>, S or a combination thereof; and R<sup>11</sup> and R<sup>12</sup> are as defined in claim 1.

- 8 -

PC 25562

Claim 32 (original): A compound of claim 29, wherein Z is  $-O-(CH_2)_{2-3}-O-(CH_2)_{1-2}$ ,  $-O-(CH_2)_{3-4}-O-$ ,  $O-(CH_2)_{1-2}-$ ,  $-(CH_2)-O-(CH_2)_{2-3}-O-(CH_2)_{0-1}-$ ,  $-C(O)-NR^{11}-(CH_2)_{2-}$ ,  $-C(O)-NR^{11}-(CH_2)_{2-}$ ,  $-C(O)-NR^{11}-(CH_2)_{2-}$ ,  $-C(O)-NR^{11}-(CH_2)_{2-}$ .

Claim 33 (canceled)

Claim 34 (original): A compound of claim 1, wherein Z is  $-O-(CH_2)_3-O-(CH_2)_-$ .

Claim 35 (original): A compound of claim 1, wherein W is unsubstituted or substituted phenyl.

Claim 36 (original): A compound of claim 1, wherein W is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-fluoro-2-trifluoromethylphenyl, 2-(2-acetoxy-ethyl)-phenyl, 3-(2-acetoxy-ethyl)-phenyl, 4-(2-acetoxy-ethyl)-phenyl, N,N-dimethyl-benzamide-4-yl, or 4-acetylaminophenyl.

Claim 37 (original): A compound of claim 1, wherein W is 2-methoxyphenyl.

Claims 38-40 (canceled)

Claim 41 (original): A compound of claim 1, wherein Z is  $-O-(CH_2)_3-O-CH_2$ , and W is 2-methoxyphenyl.

Claim 42. (currently amended): A compound of claim 1, wherein Q is -NH-CH<sub>2</sub>- or -NR<sup>8</sup>-CH<sub>2</sub>-; T is unsubstituted naphthyl, unsubstituted 4-trifluoromethylphenyl, 4-(2 ethoxy 2 excethyl) 3 exe 3,4 dihydro 2H benzo[1,4]exazin 6 yl, 3 exe 3,4 dihydro 2H benzo[1,4]exazin 6-yl, 4-(3 methoxypropyl) 3-exe 3,4 dihydro 2H benzo[1,4]exazin 6-yl, 4-(2-ethoxypropyl) 3-exe 3,4 dihydro 2H benzo[1,4]exazin 6-yl, 4-(2-

- 9 -

PC 25562

acetylaminoethyl) 3 oxo 3,4 dihydro 2H-benzo[1,4]oxazin 6 yl, 4 acetamidyl 3 oxo 3,4 dihydro 2H-benzo[1,4]oxazin 6 yl, 4 (2-acetoxyethyl) 3 oxo 3,4 dihydro 2H-benzo[1,4]oxazin 6 yl, 4-(3-methoxy 3 oxopropyl) 3 oxo 3,4 dihydro 2H-benzo[1,4]oxazin 6 yl or 4 (2-methoxy 2-oxoethyl) 3 oxo 3,4 dihydro 2H-benzo[1,4]oxazin 6; and R<sup>8</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl.

Claim 43 (canceled)

Claim 44 (previously amended): A compound of Formula IV or V

or a pharmaceutically acceptable salt thereof, wherein

T is substituted or unsubstituted aryl;

W is substituted or unsubstituted aryl; and

R<sup>17</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

Claim 45 (original): A compound of claim 44, wherein T is substituted aryl.

Claim 46. (currently amended): A compound of claim 45, wherein T is substituted phenyl, naphthyl, biphenyl, or 1,2,3,4-tetrahydro-naphthyl, 1,2,3,4-tetrahydroisoquinolinyl,

- 10 -

PC 25562

1,2,3,4-tetrahydroquinoxalinyl, 1,2,3,4-tetrahydroindolyl, 2,3-dihydroindolyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl, or 3,4-dihydro-2H-benzo[1,4]oxazinyl.

Claim 47 (currently amended): A compound of claim 44, wherein T is naphthyl er-3,4-dihydro-2H benzo[1,4]oxazinyl substituted from 1 to 7 times with, C<sub>1</sub>-C<sub>6</sub> alkyl, halo, hydroxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR<sup>16</sup>, S or a combination thereof, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-O-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-N(R<sup>16</sup>)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)-NR<sup>16</sup>-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-NR<sup>16</sup>-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, HO-C(O)-(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>0-1</sub>-, or HO-(C<sub>1</sub>-C<sub>6</sub> alkyl), wherein each R<sup>16</sup> is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl or a combination thereof.

Claim 48 (currently amended): A compound of claim 44, wherein T is unsubstituted naphthyl, or unsubstituted 4-trifluoromethylphenyl, 4 (2 othoxy 2 oxoothyl) 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin 6 yl, 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin 6 yl, 4 (2 acetylaminoethyl) 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin 6 yl, 4 acetamidyl 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin 6 yl, 4 acetamidyl 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin-6 yl, 4 (2 acetylaminoethyl) 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin-6 yl, 4 (3 methoxy 3 oxopropyl) 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin-6 yl or 4 (2 methoxy-2 oxoethyl) 3 oxo-3,4 dihydro-2H-benzo[1,4]oxazin-6 yl.

Claims 49-52 (canceled)

Claim 53 (original): A compound of claim 44, wherein W is unsubstituted or substituted phenyl.

Claim 54 (original): A compound of claim 53, wherein W is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-

PC 25562

methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2-chloro-4-fluorophenyl, 4-fluoro-2-trifluoromethylphenyl, 2-(2-acetoxy-ethyl)-phenyl, 3-(2-acetoxy-ethyl)-phenyl, 4-(2-acetoxy-ethyl)-phenyl, N,N-dimethyl-benzamide-4-yl, or 4-acetylaminophenyl.

Claim 55 (original): A compound of claim 44, wherein W is 2-methoxyphenyl.

Claim 56 (previously amended): A compound of claim 44, wherein T is unsubstituted naphthyl or unsubstituted 4-trifluoromethylphenyl and W is 2-methoxyphenyl.

## Claim 57 (previously amended): The compound

- (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-naphthalen-2-ylmethyl-amine,
- (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-(6-methoxy-naphthalen-2-ylmethyl)-amine,
- (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-methyl-naphthalen-2-ylmethyl-amine,
- 6-[(4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalen-2-ol,
- 6-[(4-[3-(2-methoxy-benzyloxy)-propoxyl]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-1-carboxylic acid methyl ester,
- 6-[(4-[4-(2-methoxy-benzyloxy)-propoxyl]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-1-carboxylic acid,
- naphthalene-1-carboxylic acid (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-amide,
- 6-[(4-{4-[3-(2-methoxy-benyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-2-carboxylic acid methyl ester,
- 6-[(4-{4-[3-(2-fluoro-benyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-2-carboxylic acid methyl ester,
- 6-[(4-{4-[3-(2-fluoro-benyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-2-carboxylic acid,

- 12 -

PC 25562

naphthalene-2-sulfonic acid (4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-amide,

(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-(4-fluoro-3-trifluoromethyl-benzyl)-amine,

{3-[(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-phenoxy}-acetic acid methyl ester,

1-(2-{3-[(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2,5-dione, or

1-(2-{3-[(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2-one.

Claim 58 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of claims 1, 44, or 57 1 19, 27-32, 34-37, 41 48, 51 58, or 67, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 59 (currently amended): A method of inhibiting renin in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1, 44, or 57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

Claim 60 (currently amended): A method of treating or preventing hypertension in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1, 44, or 57 1 19, 27 32, 34 37, 41 48, 51 58, or 67.

Claim 61 (currently amended): A method of treating or preventing congestive heart failure in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1, 44, or 57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

Claim 62 (currently amended): A method of treating or preventing stroke in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1, 44, or 57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

- 13 -

PC 25562

Claim 63 (canceled)

Claim 64 (currently amended): A method of treating or preventing glaucoma in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1, 44, or 57 1-19, 27 32, 34-37, 41-48, 51-58, or 67.

Claim 65 (canceled)

Claim 66 (currently amended): A method of treating or preventing hyperaldosteronism in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1, 44, or 57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

Claim 67 (currently amended): A process for preparing a compound of claim 1 I comprising the steps of:

a) alkylation of piperidine 1 to afford the intermediate 2 wherein R<sup>20</sup>, along with the oxygen to which it is attached, is equivalent to -Z-W as defined in claim 1;

b) oxidation of 2 to afford the piperidinone intermediate 3;

- 14 -

PC 25562

c) contacting 3 with a suitable amine to afford the intermediate 4, wherein R<sup>21</sup>, along with the nitrogen to which it is attached is equivalent to -Q-T as defined in claim 1;

d) deprotection of 4 to afford 5